Drug Profile
Research programme: neurological disorder therapies - Apollo Life Sciences
Latest Information Update: 09 Mar 2011
Price :
$50
*
At a glance
- Originator Apollo Life Sciences
- Class Proteins
- Mechanism of Action Apoptosis inhibitors; Nerve growth factor stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Alzheimer's disease; Multiple sclerosis; Neurological disorders; Stroke
Most Recent Events
- 26 May 2005 Preclinical trials in Alzheimer's disease in Australia (unspecified route)
- 26 May 2005 Preclinical trials in Multiple sclerosis in Australia (unspecified route)
- 26 May 2005 Preclinical trials in Neurological disorders in Australia (unspecified route)